Pfizer spells out PhIII talazoparib data in NEJM article; Tolero teams up with AbbVie for AML combo

David Hung offered a hard sell of his experimental PARP drug talazoparib while bidders lined up in what turned out as a $14 billion Medivation buyout by Pfizer. Now researchers are spelling out all the data in an article in the New England Journal of Medicine as Pfizer lines up a quick review and likely OK for a drug that will face some well entrenched competitors.

→ Salt Lake City-based Tolero Pharmaceuticals has struck a deal to share the costs on an upcoming combo cancer drug trial with AbbVie. Researchers will match Tolero’s alvocidib, a CDK9 drug, with AbbVie’s venetoclax for treatment resistant cases of acute myeloid leukemia.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->